How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.


Measles Virus for Immunovirotherapy of Cancer

Organization name

DKFZ Deutsches Krebsforschungszentrum



Viral therapy holds the promise for an effective and poor in side effects way of cancer treatment. During the last years several groundbreaking inventions have led to sentential improvements in therapy outcome of several different viral systems. The invention discloses a measles virus based tumour therapy.


The invention depicts a measles virus based therapeutic candidate for solid cancers and has been successfully tested in an in vivo model of melanoma.


  • Measles virus based cancer therapy
  • Virus expressing singe chain antibodies against CTLA-4 or PD-L1
  • Proven effectiveness in a syngeneic immunocompetent murine melanoma model

Development Stage

The technology has successfully been tested in animal in vivo validated studies.

The Technology

A recombinant virus of the family Paramyxoviridae virus encoding single chain antibodies against CTLA-4 or PD-L1 in alone or in combination with an immune stimulatory molecule like GM-CSF. The virus has been shown to dig increase the survival time of animals tested in a syngeneic immunocompetent murine melanoma model significantly.

Applications and Commercial Opportunity

DKFZ is looking for a partner to promote the invention towards clinical application.


The investigators are Guy Ungerechts, Christine Engeland, Sascha Bossow (all DKFZ Department of Translational Oncology, G100)

Intellectual Property

DKFZ has filed a US provisional application US 61/944,353 with a priority date February 25th in 2014.

Further Information

No other public information is currently available, but further information (speaking with the inventor) is available under a signed Confidential Disclosure Agreement (CDA).


“Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine.” by Grossardt C. et al. in Hum Gene Ther. 2013 Jul; 24(7):644-54

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.


latest entries